Issue 6, 2009

Expanding proteomics into the analysis of chiral drugs

Abstract

The chiralities of chiral drugs have been investigated extensively with the purpose of enlightening the role of chirality in drug action. Proteomics, though in its infancy, has recently emerged as the foremost technology in drug development research, possessing the advantage of providing more useful information about an organism than genomics, as it directly addresses the level of genome products and their interactions. In this review, we will discuss the background of chiral drug investigation from which contemporary drug chirality research has emerged, the techniques involved in proteomics technology, the application of proteomics in this exciting area, and the perspectives in future applications of this field.

Graphical abstract: Expanding proteomics into the analysis of chiral drugs

Article information

Article type
Review Article
Submitted
25 Feb 2009
Accepted
01 Apr 2009
First published
28 Apr 2009

Mol. BioSyst., 2009,5, 603-608

Expanding proteomics into the analysis of chiral drugs

J. Sui, J. Zhang, C. B. Ching and W. N. Chen, Mol. BioSyst., 2009, 5, 603 DOI: 10.1039/B903858B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements